View Single Post
Old 02-15-2013, 06:47 PM   #35
Junior Member
Location: Toronto, Canada

Join Date: Nov 2010
Posts: 4

Originally Posted by TonyBrooks View Post
The problem is that scaffold runs for de novo are so niche in the grand scheme of things.
Not really; I'd love to be able to quickly map out cancer genome rearrangements and a 4% error rate wouldn't bother me for that purpose.

I wonder what updates will come out next week at AGBT...
Paul Krzyzanowski
paulk is offline   Reply With Quote